Working… Menu

Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04157140
Recruitment Status : Recruiting
First Posted : November 8, 2019
Last Update Posted : December 3, 2019
Information provided by (Responsible Party):
Jinglong Chen, Beijing Ditan Hospital

Brief Summary:
A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib hydrochloride in combination with radiofrequency ablation (RFA) and transcatheter arterial chemoembolization(TACE) in patients with middle-advanced hepatocellular carcinoma(HCC)

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Drug: Anlotinib Device: TACE+RFA Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Anlotinib Hydrochloride In Combination With Radiofrequency Ablation And Transcatheter Arterial Chemoembolization in Patients With Middle-advanced Hepatocellular Carcinoma, Open, Single Arm, Exploratory Clinical Trial
Actual Study Start Date : November 28, 2019
Estimated Primary Completion Date : September 1, 2022
Estimated Study Completion Date : March 30, 2023

Arm Intervention/treatment
Experimental: Anlotinib+ TACE+ RFA
Anlotinib+ TACE+ RFA
Drug: Anlotinib
12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.

Device: TACE+RFA
TACE first, followed by RFA within day7(+/-3days)

Primary Outcome Measures :
  1. Time To Progression(TTP) [ Time Frame: each 42 days up to progressive disease (PD) (up to 24 months) ]
    Time To Progression is defined as the time from first day of TACE treatment until the first date of either objective disease progression

Secondary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: each 42 days up to intolerance the toxicity or PD (up to 24 months) ]
    Objective response rate is defined as the percentage of subjects whose best response was complete response (CR) or partial response (PR) according to the Modified Response Evaluation Criteria in Solid Tumors Version (mRECIST).

  2. Disease Control Rate (DCR) [ Time Frame: each 42 days up to intolerance the toxicity or PD (up to 24 months) ]
    Disease control rate is defined as the percentage of subjects whose best response was CR, PR or stable disease (SD) according to the mRECIST.

  3. Duration of Response (DOR) [ Time Frame: Time Frame: each 42 days up to intolerance the PD or death (up to 24 months) ]
    Duration of Response is defined as the percentage of subjects whose best response was CR, PR or stable disease (SD) according to the mRECIST or death due to any cause, whichever occurs first.

  4. Incidence of Treatment-Emergent Adverse Events [ Time Frame: Until 30 day safety follow-up visit ]
    Safety and Tolerability

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients participate in the study voluntarily and sign informed consent with good compliance.
  • Histological or cytological confirmation of unrespectable middle-advanced hepatocellular carcinoma, Barcelona Clinic Liver Cancer stage Category C or B , liver function child-Pugh class A or B (≤7 points).
  • At least one measurable lesion, with diameter ≥ 10mm measured by spiral MRI/CT scan per mRECIST; have not received local therapies including but not limited to TACE, RFA, radiotherapy and cryosurgery.-Eastern Cooperative Oncology Group Performance Status 0 or 1.
  • Life expectancy of at least 3 months.
  • Main organs function is normal. (normal main organs function as defined below: Hemoglobin (Hb) ≥ 90 g/L, Neutrophils (ANC) ≥ 1.5×109/L, leucocyte (WBC) ≥ 3.0×109/L, Platelet count (PLT) ≥ 70×109/L, Total bilirubin (TBIL) ≤ 1.5 × normal upper limit (ULN), Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 ×ULN, Serum creatinine (Cr) ≤ 1.5× ULN or Creatinine Clearance rate(CCr) ≥60ml/min,Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) > 50%)
  • The woman patients of childbearing age who must agree to take contraceptive methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 3 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 8 weeks after it.
  • Patients have disease that is not amenable to potentially curative transplantation or ablation
  • Patients who have characterization for targeted therapy treatment, but under poor economic conditions and cannot afford angiogenesis inhibitors recommended by current guidelines, including Lenvatinib, sorafenib, Cabozantinib, Ramolumab, regorafenib, etc.

Exclusion Criteria:

  • History of other malignancy within 5 years or for now (except for non-melanoma skin cancer, cervix in situ carcinoma, superficial Bladder neoplasms).
  • Subject has obstacle in the function of major organs such as heart, lung, liver and kidney
  • Patients who plan liver transplantation.
  • Patients who had previously received treatment with target inhibitors or other immunotherapy against or chemotherapy
  • Patients who had previously received treatment with TACE or or other local therapy or radiotherapy or Chinese medicine treatment within 4 weeks.
  • Liver function status Child-Pugh Class C, with malignant ascites.
  • Participated in other anti-tumor clinical trials within 4 weeks.
  • Symptoms that affect oral medication and cannot be controlled through proper treatment (such as inability to swallow, chronic diarrhoea and intestinal obstruction, etc.).
  • Any of the following coagulation functions are abnormal, including: Prothrombin time (PT)>ULN+4s, Activated partial thromboplastin time (APTT) >1.5ULN s, nternational normalized ratio (INR)>1.5
  • Patients who underwent major surgery within 4 weeks.
  • Patients who have got non remissive toxic reactions derived from any treatment, which is over level 1 in CTC AE (4.0).
  • Patients with any severe and/or unable to control diseases,including: Patients with unsatisfactory blood pressure control using antihypertensive drugs (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100) mmHg); Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QTc≥480ms) and patients with Grade 2 or higher congestive heart failure (NYHA Classification); Patients with active or unable to control serious infections, which is over level 2 in CTC AE (4.0); Patients with poorly controlled diabetes (fasting blood glucose(FBG)>10mmol/L); Patients with kidney failure who require hemodialysis or peritoneal dialysis; Patients with a history of immunodeficiency, including a positive HIV test or other acquired, congenital immunodeficiency disease, or a history of organ transplantation; Urine routine indicates that urine protein ≥ ++, and confirmed 24-hour urine protein quantitation > 1.0 g.
  • Patients whose tumors had invaded important blood vessels by imaging or who, as determined by the researchers, were likely to invade important blood vessels during follow-up trial, resulting in fatal bleeding.
  • Patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism.
  • Regardless of the severity, patients with any physical signs or history of bleeding, patients with bleeding or bleeding events greater than or equal to CTCAE 3 within four weeks prior to the first administration, or patients with unhealed wounds, fractures, ulcers.
  • Patients with Brain metastases.
  • Patients with cancer thrombus involving whole the main portal vein.
  • Female patients who are pregnant or breastfeeding.
  • Patients with drug abuse history and unable to get rid of or patients with mental disorders.
  • Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment.
  • History of gastrointestinal bleeding due to severe gastroesophageal varices within 4 weeks.
  • Severe active or uncontrolled infections.
  • Patients who had serious adverse effect to Anlotinib.
  • Patients who had serious adverse effect to iodinated contrast agent.
  • Liver cirrhosis, hepatic decompensation, active hepatitis or chronic hepatitis which requires anti-viral treatment. Hepatitis C virus (HCV) antibody test shows positive and titer test shows amount of HCV exceeds upper limit of normal (ULN) after treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04157140

Layout table for location contacts
Contact: XiaoYan Ding, M.D 13811560276 ext +86

Layout table for location information
China, Beijing
Beijing Ditan Hospital, Capital Medical University Recruiting
Beijing, Beijing, China, 100011
Contact: Xiaoyan Ding, M.D.    13811560276 ext +86   
The First Affiliated Hospital of Dalian Medical University Not yet recruiting
Dalian, China
Contact: Feng Wang         
Shengjing Hospital Of China Medical University Not yet recruiting
Shenyang, China
Contact: Zaiming Lu         
Sponsors and Collaborators
Jinglong Chen

Layout table for additonal information
Responsible Party: Jinglong Chen, Chief of Oncology, Beijing Ditan Hospital Identifier: NCT04157140     History of Changes
Other Study ID Numbers: 320.6750.19089-49
First Posted: November 8, 2019    Key Record Dates
Last Update Posted: December 3, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jinglong Chen, Beijing Ditan Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Estrogens, Non-Steroidal
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents